Why is IGF-1 DES considered more potent than regular IGF-1?

Removing the first three amino acids greatly lowers its affinity for IGF-binding proteins. More of the peptide stays free and available to bind the IGF-1 receptor, increasing its localized biological activity.

How does IGF-1 DES differ from IGF-1 LR3?

Both resist binding proteins, but DES is a short-acting truncated form favored for localized effects, whereas LR3 is engineered for a much longer half-life and more systemic activity.

← All peptides

Muscle Growth

Research Chemical

IGF-1 DES

Also known as: IGF-1 DES, IGF-DES

IGF-1 DES is a truncated variant of insulin-like growth factor 1 missing the first three N-terminal amino acids, studied for potent, localized anabolic and tissue-growth effects. It is noted for higher activity at the site of injection.

Mechanism of Action

IGF-1 DES (1-3) lacks the N-terminal tripeptide of native IGF-1, which dramatically reduces its binding to IGF-binding proteins (IGFBPs). With less sequestration by IGFBPs, more free peptide is available to activate the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase that drives PI3K/Akt and MAPK signaling to promote cell proliferation, protein synthesis, and hypertrophy. Its short half-life and reduced binding tend to concentrate activity in the tissue where it is administered.

Half-life: Very short; roughly 20 to 30 minutes
Administration Routes: subcutaneous
Research Status: Research Chemical